Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
Enliven Therapeutics, Inc. ELVN
$51.55
▲ +4.29%
(+$2.12)
Open
$49.88
Prev Close
$49.43
Day Range
$48.77 – $51.86
52W Range
$14.79 – $62.32
Market Cap
$3.62B
Beta
0.65
EPS (TTM)
$-1.67
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-03-12 |
| Shares Out. | 73,270,000 |
| Website | enliventherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 65 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$32.5M |
| Free Cash Flow | -$67.0M |
| Total Assets | $910.2M |
| Total Liabilities | $15.1M |
| Equity | $895.1M |
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics, Inc. is a publicly traded company under the ticker symbol ELVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-11-01)